Novel Once-Weekly Basal Insulins: Expert Interpretation of Latest Clinical Data

Newer oral glucose-lowering agents have revolutionized the treatment of type 2 diabetes (T2D), yet up to 40% of people across the globe still require insulin.

Credit available for this activity expires: 10/18/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/982624?src=mkm_podcast_series_982624